TBPH Stock Overview
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia.
Notes are coming soon
Theravance Biopharma, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$10.62|
|52 Week High||US$11.83|
|52 Week Low||US$7.53|
|1 Month Change||-5.35%|
|3 Month Change||10.05%|
|1 Year Change||15.94%|
|3 Year Change||-64.60%|
|5 Year Change||-56.55%|
|Change since IPO||-53.75%|
Recent News & Updates
Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) ForecastsNov 11
Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's DowngradeSep 21
Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%Aug 09
Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This YearMay 09
Shareholders May Not Be So Generous With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation And Here's WhyApr 21
Don't Ignore The Fact That This Insider Just Sold Some Shares In Theravance Biopharma, Inc. (NASDAQ:TBPH)Mar 13
Is Theravance Biopharma, Inc. (NASDAQ:TBPH) Expensive For A Reason? A Look At Its Intrinsic ValueMar 08
Would Shareholders Who Purchased Theravance Biopharma's (NASDAQ:TBPH) Stock Year Be Happy With The Share price Today?Feb 01
Don't Ignore The Fact That This Insider Just Sold Some Shares In Theravance Biopharma, Inc. (NASDAQ:TBPH)Dec 09
|TBPH||US Pharmaceuticals||US Market|
Return vs Industry: TBPH exceeded the US Pharmaceuticals industry which returned 4.5% over the past year.
Return vs Market: TBPH exceeded the US Market which returned -9.2% over the past year.
|TBPH Average Weekly Movement||5.5%|
|Pharmaceuticals Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||17.3%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: TBPH is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: TBPH's weekly volatility (6%) has been stable over the past year.
About the Company
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn’s disease.
Theravance Biopharma, Inc. Fundamentals Summary
|TBPH fundamental statistics|
Is TBPH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TBPH income statement (TTM)|
|Cost of Revenue||US$91.40m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.05|
|Net Profit Margin||-136.98%|
How did TBPH perform over the long term?See historical performance and comparison